CRDL

Cardiol Therapeutics Inc

1.12

Oct 26 • 3:59 PM ET 0.00 (0.00%)

1.13

Aftermarket • 7:30 PM ET +0.01 (0.89%)

Healthcare Drug Manufacturers - Specialty & Generic Canada Micro NASD

Peers: KNSA CPIX IXHL TENX MIST CYTK LXRX INM MNKD JAZZ

| Held by: GWX

Scroll to Statements

Index	-
Market Cap	135.14M
Enterprise Value	116.84M
Income	-24.69M
Sales	0.00M
Book/sh	0.15
Cash/sh	0.15
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	23
IPO	Jan 15, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	7.66
P/C	7.35
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.55
Current Ratio	5.55
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.25
EPS next Y	-0.22
EPS next Q	-0.06
EPS this Y	-12.62%
EPS next Y	28.73%
EPS next 5Y	71.75%
EPS past 3/5Y	9.88% 11.60%
Sales past 3/5Y	- -
EPS Y/Y TTM	28.85%
Sales Y/Y TTM	-
EPS Q/Q	47.67%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	48.49% -

Insider Own	2.93%
Insider Trans	0.00%
Inst Own	25.59%
Inst Trans	2.88%
ROA	-139.86%
ROE	-192.95%
ROIC	-145.37%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-11.74%
SMA50	-33.37%
SMA200	-13.84%
Trades

Shs Outstand	120.66M
Shs Float	117.12M
Short Float	2.62%
Short Ratio	2.19
Short Interest	3.07M
52W High	2.34 -52.14%
52W Low	0.88 27.27%
Volatility	4.66% 6.16%
ATR (14)	0.08
RSI (14)	26.59
Beta	1.02
Rel Volume	0.41
Avg Volume	1.40M
Volume	580,163

Perf Week	1.82%
Perf Month	-34.50%
Perf Quarter	-6.67%
Perf Half Y	-20.00%
Perf YTD	17.43%
Perf Year	-5.88%
Perf 3Y	39.95%
Perf 5Y	-73.89%
Perf 10Y	-
Recom	1.00
Target Price	7.89
Prev Close	1.12
Price	1.12
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-26-26	Initiated	B. Riley Securities	Buy	$11
Jun-02-25	Initiated	H.C. Wainwright	Buy	$9
Jan-28-25	Initiated	Rodman & Renshaw	Buy	$7
Jun-26-24	Initiated	ROTH MKM	Buy	$10
Apr-22-24	Initiated	H.C. Wainwright	Buy	$9

Sep-23-26 06:00AM	Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx's Efficacy (PR Newswire) -6.35%
Sep-16-26 07:27AM	Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds (PR Newswire)
Sep-10-26 05:00PM	Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission (PR Newswire) -13.35%
Sep-09-26 07:27AM	Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
Aug-05-26 07:27AM	Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference (PR Newswire)
07:27AM	Loading…
Jul-14-26 07:27AM	Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association (PR Newswire) +8.49%
Jul-09-26 07:27AM	Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit (PR Newswire)
Jun-25-26 07:27AM	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders (PR Newswire)
Jun-23-26 07:27AM	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT (PR Newswire)
May-14-26 07:27AM	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ (PR Newswire)
May-07-26 07:27AM	Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association (PR Newswire)
Apr-28-26 07:27AM	Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program (PR Newswire)
Apr-20-26 12:00AM	Upcoming Meeting Dates - April 20, 2026 (Newsfile)
Apr-14-26 07:27AM	Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart (Newsfile)
Apr-01-26 07:27AM	Cardiol Therapeutics Announces Year-End 2025 Update on Operations (Newsfile)
07:02PM	Loading…
Mar-08-26 07:02PM	Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference (MarketBeat)
Mar-03-26 08:07AM	Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-25-26 07:27AM	Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference (Newsfile)
Feb-10-26 07:27AM	Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure (Newsfile)
Jan-23-26 09:16AM	Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million (Newsfile Corp.)
Jan-16-26 08:46AM	Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million (Newsfile) +10.07%
08:42AM	Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million (Newsfile)
Jan-13-26 07:27AM	Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis (Newsfile)
Dec-01-25 07:27AM	New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions (Newsfile) -9.52%
Nov-13-25 07:45AM	Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 (TMX Newsfile)
Nov-05-25 07:45AM	Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases (Newsfile)
Oct-21-25 07:27AM	Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 (TMX Newsfile) +15.24%
Oct-17-25 04:34PM	Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027 (Newsfile)
Oct-15-25 06:19AM	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks)
Oct-14-25 10:57AM	5 Small Drug Stocks to Buy as the Industry Shows Some Recovery (Zacks)
07:27AM	Loading…
Aug-11-25 07:27AM	Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference (Newsfile)
Aug-06-25 07:27AM	Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis (Newsfile) -20.74%
Jul-22-25 07:27AM	Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis (Newsfile) +14.75%
May-29-25 07:27AM	Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders (Newsfile)
May-27-25 07:27AM	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT (Newsfile) +5.45%
Apr-29-25 07:27AM	Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors (Newsfile) +6.48%
Apr-22-25 07:21AM	Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? (Zacks)
Apr-16-25 07:27AM	Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis (Newsfile)
Apr-01-25 07:27AM	Cardiol Therapeutics Announces Year-End 2024 Update on Operations (Newsfile)
Mar-03-25 07:27AM	Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (Newsfile) -5.22%
Feb-20-25 07:27AM	Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure (Newsfile) +6.56%
Feb-04-25 07:27AM	Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (Newsfile) +5.26%
Dec-19-24 08:30AM	PRISM MarketView Features QandA with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis (GlobeNewswire)
08:30AM	PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis (GlobeNewswire)
Nov-18-24 11:37AM	Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 (Newsfile)
Nov-13-24 08:00AM	Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index (GlobeNewswire)
Oct-22-24 02:30AM	Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis (Newsfile)
Oct-11-24 08:39AM	Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option (Newsfile) +5.62%
Oct-10-24 09:09AM	Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares (Newsfile)
Oct-09-24 07:58AM	Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares (Newsfile) -6.63%
Oct-08-24 04:01PM	Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares (Newsfile)
Sep-24-24 07:27AM	Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis (Newsfile)
Sep-10-24 07:27AM	Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 (Newsfile) +5.03%
Aug-12-24 10:53PM	CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024 (InvestorPlace)
Jun-27-24 12:29PM	Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders (Newsfile)
Jun-25-24 07:27AM	Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT (Newsfile) +6.00%
Jun-17-24 07:00AM	Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients (News Direct) -8.71%
Jun-13-24 07:58AM	Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis (Newsfile) -20.54%
Jun-11-24 06:00AM	Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development (News Direct)
Jun-03-24 07:00AM	Sector Spotlight: Orphan Drug Developers With Significant Upside (News Direct) +6.11%
May-28-24 07:00AM	Analysts' Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (News Direct)
May-14-24 10:53PM	CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024 (InvestorPlace) +6.42%
07:27AM	Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024 (Newsfile)
May-13-24 12:19PM	Canadian Investment Regulatory Organization Trading Halt - CRDL.WT.A (PR Newswire)
Apr-02-24 09:53AM	CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.73%
06:00AM	Cardiol Therapeutics Announces Year-End 2023 Update on Operations (Newsfile)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey) -10.20%
Feb-21-24 07:27AM	Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis (Newsfile) -11.98%
Feb-15-24 07:27AM	Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis (Newsfile) +42.31%
Jan-24-24 07:27AM	Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market (Newsfile) -5.36%
Jan-09-24 07:27AM	Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis (Newsfile)
Dec-05-23 07:27AM	Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot (Newsfile)
Nov-16-23 05:30AM	Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases (Newsfile)
Nov-01-23 07:27AM	Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis (Newsfile)
Oct-20-23 05:00PM	Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (Newsfile) -6.76%
Oct-13-23 09:24AM	Cardiol Therapeutics (NASDAQ: CRDL)Advancements in Therapies for Inflammatory Heart Diseases (News Direct) -18.00%
Oct-11-23 01:05PM	Cardiol Therapeutics releases positive study results of subcutaneously administered cannabidiol (News Direct)
Oct-10-23 06:00AM	Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction (Newsfile) +14.22%
Sep-27-23 09:34AM	Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock (Zacks)
Sep-26-23 07:27AM	Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference (Newsfile)
Sep-19-23 07:27AM	Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis (Newsfile)
Aug-09-23 07:27AM	Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference (Newsfile)
Aug-08-23 07:27AM	Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market (Newsfile) -13.45%
Jun-29-23 10:19AM	Cardiol Therapeutics Reports Results of 2023 Annual General Meeting (Newsfile) +11.96%
Jun-27-23 07:27AM	Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT (Newsfile)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE) +8.68%
Mar-29-23 07:27AM	Cardiol Therapeutics Announces Year-End 2022 Update on Operations (Newsfile)
Mar-07-23 07:27AM	Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure (Newsfile)
Jan-17-23 02:59PM	Cardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for Pericarditis (News Direct)
07:27AM	Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis (Newsfile)
Dec-12-22 07:27AM	Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent Pericarditis (Newsfile) +7.30%
Nov-14-22 05:00PM	Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (Newsfile)
Nov-07-22 07:27AM	Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx(TM) in a Model of Acute Pericarditis (Newsfile)
Oct-25-22 06:30AM	Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases (Newsfile) +12.99%
Oct-03-22 07:27AM	Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis (Newsfile)
Sep-28-22 08:20AM	Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America (Newsfile) +11.76%
Sep-27-22 09:05AM	60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago (ACCESSWIRE) -7.27%
Aug-03-22 07:29AM	Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis (Newsfile)
Jul-12-22 06:14AM	Cardiol Therapeutics Inc. (TSE:CRDL): Are Analysts Optimistic? (Simply Wall St.)
Jun-29-22 10:07AM	Cardiol Therapeutics Reports Results of 2022 Annual General Meeting (Newsfile) -8.72%

Show Previous News

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

PresidentMr. David G. Elsley MBA

C.M.A.Mr. Christopher J. Waddick C.A.

Chief Operating OfficerMr. Bernard Lim B.Sc.

Chief Medical Officer and Head of Research & DevelopmentDr. Andrew Warwick Hamer M.D.

Investor RelationsTrevor Burns

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRDL

Cardiol Therapeutics Inc

Upgrade your Finviz experience